KALV
KalVista Pharmaceuticals, Inc. · Healthcare
Chief Development Officer Christopher Yea sold $68K of KalVista Pharmaceuticals, Inc.
Sold$67,669
$15.57Price
4,347Shares
−2%Stake
What KALV did after the filing
- The stock from Tue, Feb 24 close, $15.77
- +22.2%
- S&P 500, same days
- −1.6%
Measured over 30 trading days, to the Apr 8 close.
Traded Mon, Feb 23. Filed Tue, Feb 24, 2:43 PM ET, during the session. Returns use the Feb 24 close and the Apr 8 close. Not investment advice.